New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Revolutionizing Atopic Dermatitis

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!

Diabetes Dialogue: Bionic Pancreas Brings AID to Primary Care & Telehealth

New research underlines the feasibility of telehealth- and primary care-led initiation of automated insulin delivery (AID) among patients with 

A multisite, random-order crossover trial of 40 adults with type 1 diabetes, study results suggest 97% of participants achieved a mean glucose less than 8% (183 mg/dL) and 64% achieved a mean glucose less than 7% (154 mg/dL) when using the iLet Bionic Pancreas.

“These findings suggest that this device, with its uniquely simplified initialization and use, may expand access to AID technology to more patients who otherwise may be limited by geography and/or access limitations to subspecialty care," wrote investigators. 

A clinical trial led by Sean Oser, MD, MPH, and Tamara Oser, MD,  and conducted between March 2022 and May 2023, the study was designed to evaluate the use of the iLet Bionic Pancreas for insulin delivery in individuals with type 1 diabetes across primary care and endocrinology settings, including both in-person and telehealth subgroups.

Per trial protocol, participants completed 2, 14-day study arms in randomized order. One study arm involved use of the iLet Bionic Pancreas and the other required patients to their usual care insulin regimen, which was defined as multiple daily injections with or without continuous glucose monitoring for primary care and automated insulin delivery or insulin pump with or without continuous glucose monitoring for endocrinology.

The primary outcome was the percentage of participants achieving a mean glucose level of less than 183 mg/dL, which is representative of a glucose management indicator of less than 8.0%. The trial’s key secondary outcome included achievement of a mean glucose level of less than 154 mg/dL, which is representative of a glucose management indicator of less than 7.0%).

The 40-patient study cohort had a mean age of 44.8 (SD, 14.0) years, 43% were female, and 85% were White). At baseline, the primary care group had a mean a HbA1c of 6.9% (SD, 0.8%) and the endocrinology group had a mean HbA1c of 7.2% (SD, 0.8%). Of note, a single patient was lost to follow-up as the result of a seizure unrelated to study procedures during the usual care portion and never participated in the intervention arm.

Results of the study suggested 97% of participants achieved a mean glucose level less than 183 mg/dL and 64% reached less than 154 mg/dL. Further analysis of study data revealed no differences in glucose levels among those attending primary care and endocrinology nor were any differences observed between initiation with telehealth and in-person settings (

Additionally, investigators pointed out the iLet Bionic Pancreas demonstrated consistent performance across mean glucose levels, time in range, time above 180 mg/dL, time above 250 mg/dL, time below 54 mg/dL, and glucose variability.

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, take a deep dive into this study and discuss the role of primary care in diabetes technology uptake in type 1 diabetes.

Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others.

Oser SM, Putman MS, Russell SJ, et al. Assessing the iLet Bionic Pancreas Deployed in Primary Care and via Telehealth: A Randomized Clinical Trial. 

. Published online February 24, 2025. doi:10.2337/cd24-0104

Podcasts

In this episode, hosts discuss a study assessing the benefit and feasibility of AID for type 1 diabetes with the iLet Bionic Pancreas in different settings.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Type 1 Diabetes

Type 2 Diabetes

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Videos

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

XORTX has announced that it will have a Type B meeting with the FDA to review chemistry, manufacturing, pharmacology, toxicology and clinical evidence regarding its XRx-026 program for the treatment of gout.

The company’s XRx-026 program is developing a formulation of oxypurinol termed XORLO. The meeting will assess the therapy’s readiness for a new drug application (NDA).

“We look forward to FDA feedback the last week in April and advancing the XRx-026 program, thereafter. Many key elements of the XRx-026 program have advanced sufficiently to warrant this robust program review with the FDA to define any additional information needed to complete this marketing approval. We believe that the XRx-026 program provides a much needed therapeutic option for individuals with gout and that advancing with the XRx-026 program will transform XORTX to a revenue positive state,” Allen Davidoff, CEO of XORTX, said in a statement.

Other recent research into gout found that an interpretable machine learning (ML) model was feasible for predicting gout and may establish a foundation for future applications in supporting gout diagnosis.

“The integration of ultrasound data into ML algorithms could provide a more comprehensive approach to gout diagnosis, combining the advantages of both imaging diagnostics and artificial intelligence. Furthermore, while existing ML models for gout prediction have shown promise, their clinical applicability has been limited by a lack of interpretability concerning their decision-making processes,” lead investigator Lishan Xiao, Department of Ultrasound, the Affiliated Hospital of Qingdao University, Qingdao, China, and colleagues wrote.

The investigators included data from 609 patients’ first metatarsophalangeal (MTP1) joint ultrasound from 2 institutions. Institution 1 data (n = 571) were split into training cohort (TC) and internal testing cohort (ITC) in an 8:2 ratio, and Institution 2 data (n = 92) served as an external testing cohort (ETC). Key predictors were selected using Random Forest (RF), Least Absolute Shrinkage and Selection Operator (LASSO), and Extreme Gradient Boosting (XGBoost) algorithms. Xiao and colleagues evaluated 6 ML models using standard performance metrics, with SHapley Additive exPlanations (SHAP) analysis for model interpretation.

Xiao and colleagues identified 5 key predictors of gout: serum uric acid (SUA), deep learning (DL) model predictions, tophus, bone erosion, and double contour sign (DCs). They achieved optimal predictive performance using a logistic regression (LR) model which had an Area Under the Curve (AUC) of 0.870 (95% CI, 0.820–0.920) in ITC and 0.854 (95% CI, 0.804–0.904) in ETC. The model had good calibration, with Brier scores of 0.138 in ITC and 0.159 in ETC.

“This study developed an interpretable ML model for gout prediction and utilized SHAP to elucidate feature contributions, establishing a foundation for future applications in clinical decision support for gout diagnosis,” Xiao and colleagues wrote.

XORTX Announces Update for Discussion with the FDA. News release. XORTX. March 19, 2025. 

https://www.globenewswire.com/news-release/2025/03/19/3045235/0/en/XORTX-Announces-Update-for-Discussion-with-the-FDA.html

Xiao L, Zhao Y, LI Y, et al. Developing an interpretable machine learning model for diagnosing gout using clinical and ultrasound features. 

 2025: 184(111959) doi: 10.1016/j.ejrad.2025.111959

Articles

XORTX is meeting with the FDA in a Type B meeting regarding a potential NDA for XORLO.

Gout

On the HCPLive gout page, resources on the topics of medical news and expert insight into gouty arthritis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on gout, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Oxypurinol Formulation May Be Adapted for Gout Treatment

Connor Iapoce is the assistant managing editor for 

joining the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to the movies, and playing with his cat, Squish. You can reach him at 

Automated insulin delivery (AID) with Control-IQ+ technology led to a superior reduction in hemoglobin A1c (HbA1c) than continuous glucose monitoring (CGM) alone in adults with 

Conducted across 21 clinical centers in the U.S. and Canada, the 13-week trial randomly assigned 319 participants with insulin-requiring T2D in a 2:1 ratio to either the Control-IQ+ AID or their usual insulin-delivery method with a real-time CGM, representing a racially and socioeconomically diverse patient population.

“These results demonstrate the substantial value of Control-IQ+ technology for people with T2D who use insulin,” said Roy W. Beck, MD, PhD, medical director of the Jaeb Center for Health Research.

 “It was encouraging that even people using insulin plus a glucagon-like peptide 1 (GLP-1) receptor agonist drug, such as Ozempic, had substantial A1C improvement with the addition of Control-IQ+ to their treatment regimen.”

The benefits of AID technology for people with type 1 diabetes (T1D) are well established, but its efficacy and safety in individuals with T2D remain uncertain.

 While medications such as GLP-1 receptor agonists and sodium-glucose cotransporter 2 (SGLT2) inhibitors help many with T2D to achieve HbA1c levels of ≤7%, those with persistently elevated levels may benefit from AID systems.

The primary goal of the 13-week study was to assess changes in HbA1c after the Control-IQ+ system in adults with T2D, along with secondary measures such as CGM-measured time in range, time in hyperglycemia, time in hypoglycemia, and safety outcomes, including severe hypoglycemia and diabetic ketoacidosis.

Among the 319 participants, 39% identified as a minority race or ethnicity, including 22% Black and 11% Hispanic. Additionally, 44% were on a stable dose of a GLP-1 receptor agonist, and 37% were taking an SGLT2 inhibitor, both of which were continued during the study. Before enrollment, 96% of participants used multiple daily insulin injections, with 75% receiving fixed-dose mealtime insulin.

The trial was completed by 211 of 215 patients (98%) in the AID group and 102 of 104 (98%) patients in the control group. Upon analysis at 13 weeks, the mean HbA1c levels decreased by 0.9% (8.2% to 7.3%) with AID and by 0.3% (8.1% to 7.7%) in the control group (mean adjusted difference, –0.6% [95% CI, –0.8 to –0.4]; 

For patients with high baseline HbA1c (≥9%), mean levels were reduced from 10.3% to 7.9% in the AID group and from 9.7% to 8.6% in the control group (mean difference, –1.0%; 95% CI, –1.5 to –0.5). Time in the target glucose range (70–180 mg/dL) increased from 48% to 64% in the AID group and from 51% to 52% in the control group (mean difference, 14% [95% CI, 11–17]; 

Beck and colleagues noted this difference represented a mean time in the target glucose range that was approximately 3.4 hours per day longer for the AID group than the control group. They found the treatment effects evident in the first week were sustained across the 3-month study period.

Other multiplicity-controlled CGM outcomes reflective of hyperglycemia, including mean glucose, time >180 mg/dL, time >250 mg/dL, and the rate of prolonged hyperglycemic events, were all reduced in the AID group. CGM-measured hypoglycemia showed a low frequency at baseline and remained low during the study period.

Further analysis revealed a reduction in total daily insulin dose in the AID group (–8 units/day), compared with the CGM group (+2 units/day). Investigators stressed there were no new safety signals unique to T2D users versus previous T1D studies—a single severe hypoglycemic event was identified in the AID group and resolved via oral carbohydrates.

“These results underscore the potential of this technology to improve outcomes for people living with T2D who use insulin, while helping alleviate daily therapy burden and improve quality of life,” said Jordan Pinsker, MD, chief medical officer of Tandem Diabetes Care.

Kudva YC, Raghinaru D, Lum JW, et al. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. N Engl J Med. Published online March 19, 2025. doi:10.1056/NEJMoa2415948

Tandem Diabetes Care announces NEJM publication of positive pivotal study outcomes with control-IQ+ aid technology in type 2 diabetes. Tandem Diabetes Care. March 19, 2025. Accessed March 19, 2025. 

https://investor.tandemdiabetes.com/news-releases/news-release-details/tandem-diabetes-care-announces-nejm-publication-positive-pivotal?_gl=1%2A1hc8pow%2A_gcl_au%2AMTA5MTAyNTMwNS4xNzQyMzAzNDM3

Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. 

. 2019;381(18):1707-1717. doi:10.1056/NEJMoa1907863

American Diabetes Association Professional Practice Committee . 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2025. 

. 2025;48(Supplement_1):S181-S206. doi:10.2337/dc25-S009


AID technology outperformed CGM alone to reduce HbA1c, without increasing hypoglycemia, in adults with insulin-treated type 2 diabetes.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Automated Insulin Delivery Effectively Lowers HbA1c in Type 2 Diabetes

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

Recent findings demonstrate that lower doses of doxycycline, a commonly used antibiotic and anti-inflammatory medication, may help patients effectively manage symptoms and reduce side effects of 

Lymphocytic scarring alopecia is a rare immune-related condition that results in permanent hair loss. This analysis was conducted by an investigative team at NYU Langone Health, led by co-senior author Kristen Lo Sicco, MD, an associate professor in the Ronald O. Perelman Department of Dermatology at NYU Grossman School of Medicine.

“Alopecia can have a devastating effect on self-image and can lead to social judgment, depression, and anxiety,” Lo Sicco said in a statement.

 “Studies that advance the management of these conditions are critical to addressing not only hair loss itself but also the psychological and social consequences that accompany it.”

Lymphocytic scarring alopecia is a rare skin disease in which the immune system attacks patients’ hair follicles. Lo Sicco and colleagues noted that the condition is typically treated with high doses of doxycycline for extended treatment periods.

 However, they highlighted that a regimen using doxycycline has been linked with side effects like vomiting, nausea, and rashes, consequently leading to cessation of the medication.

In order to address the potential discontinuation of doxycycline, the investigators looked into whether lower doses of the antibiotic could provide those reporting lymphocytic scarring alopecia with the same therapeutic benefits. The team looked at 241 male and female patients’ electronic medical records, specifically those treated for scarring alopecia at NYU Langone Health between 2009 and 2023.

Learn more about the annual Revolutionizing Atopic Dermatitis (RAD) Conference

, hosted by HCPLive Dermatology Times, and our CE/CME partner Physicians’ Education Resource.

The team carried out statistical analyses intending to compare outcomes between the low and high-dose groups, excluding any influence from other treatments commonly used alongside doxycycline, such as minoxidil. They highlighted that approximately 27% had given a prescription for low-dose doxycycline (typically 20 mg twice per day), adding that close to 73% had been given the typical high-dose regimens (up to 100 mg twice per day).

In their assessment of data from the 241 subjects with lymphocytic scarring alopecia, the research team did not identify any significant differences in efficacy between the results of those in the low-dose and high-dose doxycycline arms of their research. In both of the treatment groups, the team found that comparable outcomes had been reported in terms of perceived severity of hair loss, scalp inflammation, and clinical assessments of hair-shaft thickness, hair density, and receding hairlines.

When looking at both regimens’ side effects, the investigators found that 23% of individuals in the high-dose arm were shown to have adverse reactions commonly linked to the use of doxycycline, whereas only 12% of subjects in the lower-dose arm of the analysis reported such effects.

 Additionally, while 25% of individuals in the high-dose group discontinued treatment due to gastrointestinal issues, only 16% of subjects in the low-dose arm terminated the medication for the same reason.

According to the researchers, this is the first study to directly compare varying dosages of doxycycline for the treatment of individuals with lymphocytic scarring alopecia.

“These findings indicate that physicians can effectively prescribe lower doses of doxycycline for patients with lymphocytic scarring alopecia without compromising its anti-inflammatory benefits,” co-lead author Carli Needle, BA, NYU Grossman School of Medicine, said in a statement.

Needle further expressed that although doxycycline can disrupt beneficial gut bacteria, prior research has suggested that doses of the antibiotic under 40 mg may be less likely to harm these microbes. Beyond improving patient tolerability, lowering doxycycline doses may also help combat antibiotic resistance.

The study's authors also noted that excessive doxycycline implementation has been linked to the emergence of antibiotic-resistant bacterial strains. As a result, they wrote that medical professionals worldwide are emphasizing antibiotic stewardship—a strategy aimed at diminishing antibiotic prescriptions deemed to be unnecessary as a means to mitigate antibiotic resistance.

“Our results offer another avenue for healthcare providers to protect patients from harm caused by unnecessary antibiotic use and address the rise of drug-resistant strains of microbes,” co-author Anna Brinks, BA, NYU Grossman School of Medicine, said in a statement.

The investigative team noted their plan to repeat their research using a larger and more diverse patient population, as those involved as trial participants were predominantly White.

Needle C, Brinks A, Sicco K. Efficacy and Tolerability of Low-Dose Versus High-Dose Doxycycline in the Management of Lymphocytic Scarring Alopecias. Journal of the American Academy of Dermatology, 2025, ISSN 0190-9622. 

https://doi.org/10.1016/j.jaad.2025.02.028

Low doses of antibiotic work just as well as higher ones to treat rare type of chronic hair loss. News release. NYU Langone Health / NYU Grossman School of Medicine. March 18, 2025. 

https://www.eurekalert.org/news-releases/1076645

These recent data demonstrate small doses of doxycycline, an anti-inflammatory medication, may help manage lymphocytic scarring alopecia.

Alopecia

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Low-Dose Doxycycline Effective for Managing Lymphocytic Scarring Alopecia Symptoms

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

When to Refer a Patient with Suspected ISM to an Allergist, with Patricia Lugar, MD

 workshop on November 21, 2024, called “Best Practices in Managing Indolent Systemic Mastocytosis (ISM),” 

spoke with participant Patricia Lugar, MD, allergy and immunology specialist at the Duke Asthma, Allergy, and Airway Center, to continue the discussion on 

allergic manifestations and diagnostic clues of ISM

could indicate the presence of a mast cell disease. For instance, while anyone could have an allergic reaction to bees, people with a mast cell disease may present mostly cutaneous symptoms—flushing, blotchiness in the skin, and a visible rash. It is also common for people with mast cell disorders to have syncope, lightheadedness, shortness of breath, tachycardia, and some cardiopulmonary symptoms along with cutaneous symptoms.

But when should a clinician refer a patient with suspected or confirmed ISM to an allergist?

“I like to see patients in all steps of suspicion,” Lugar said. “I love it when the GI doc, the primary care group, or whoever’s seeing the patient [and] knows the patient well, is first availing the patient for a constellation of symptoms and raises this question to grab a tryptase. That helps me out quite a bit because it lets me know what my level of suspicion might be and how to do the diagnostic evaluation next.”

A serum tryptase test helps distinguish clonal mast cell disorders, such as systemic mastocytosis, and other mast cell disorders. Even if the patient has no mast cell disorder, an allergist can still treat the reactions.

However, if it is a suspected mast cell disease, an allergist can refer the patient to colleagues who can provide a true diagnosis. For example, a patient may need a bone marrow exam.

Lugar said some misconceptions about ISM are what can and cannot trigger allergic reactions in someone with a clonal mast cell disorder. She added how it is challenging when patients ask, “Can you do a skin test for that?” or “Tell me everything I’m allergic to because I want to start a new medication.”

“Well, I wish I could, but I can't,” Lugar said. “I can't tell you what statin they're going to tolerate, what blood pressure medicine they're going to tolerate, because we don't have direct guidance often on how the exposures are interacting with this particular patient… It's a little bit of trial and error.”

For more insights on diagnosing indolent systemic mastocytosis as well as to learn more about managing indolent systemic mastocytosis, read Best Practices in Managing Indolent Systemic Mastocytosis (ISM): Disease Mechanisms, Diagnostic Challenges, and Multidisciplinary Treatment Strategies 

Relevant disclosures for Lugar include Blueprint Medicines Corporation, Grifols USA, BioCryst US Scales, and Grifols Shared Services North America.

Derman, C. Indolent Systemic Mastocytosis’ Diagnostic Clues, with Patricia Lugar, MD. HCPLive. March 19, 2025. 

https://www.hcplive.com/view/indolent-systemic-mastocytosis-diagnostic-clues-with-patricia-lugar-md

Best Practices in Managing Indolent Systemic Mastocytosis (ISM). OncLive. February 19, 2025. https://www.onclive.com/view/best-practices-in-managing-indolent-systemic-mastocytosis-ism-. Accessed March 18, 2025.

Lugar spoke with HCPLive about when to refer patients with suspected ISM to an allergist, highlighting allergic manifestations, diagnostic clues, and misconceptions.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

In the RADIcAL-1 trial, mpMRI with LiverMultiScan reduced liver biopsies, led to fewer specialist consultations, and improved MASLD diagnosis rates.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Multiparametric MRI Cost-Effective for Noninvasively Identifying, Managing MASLD

A newly passed bill permits 2.8% Medicare physician payment cuts.

Psoriatic Arthritis

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.

AMA, ACR, Others Say Medicare Cuts Will Impact Access to Care

Christopher J. Sayed, MD, is a professor of dermatology at the University of North Carolina School of Medicine. He is also the director of its HS clinic.

This interview with Christopher Sayed, MD, features a discussion about his team’s recent findings on bimekizumab for hidradenitis suppurativa.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Bimekizumab and Unmet Needs of Patients with HS, with Christopher J. Sayed, MD

New ACP migraine guidelines recommend adding a triptan to NSAIDs or acetaminophen for better relief. Combination therapy offers greater pain relief and fewer rescues.

Migraine

The HCPLive migraine page is a comprehensive resource for clinical news and insights on migraine headaches. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for migraines, and more.

New ACP Guidelines Recommend Adding Triptan to NSAID or Acetaminophen for Migraines

The success of community-based point-of-diagnosis HCV treatment in the NOW trial was attributable to collaborative care with an integrated pharmacy team.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Collaborative HCV Care with Pharmacists Could Address System-Level Treatment Barriers

Mukkamala discussed other priorities the AMA’s Substance Use and Pain Care Task Force is tackling with OUD.

Addiction

Addiction medicine condition center page, resources on the topics of medical news and expert insight into clinical addiction can be found. Content includes articles, interviews, videos, podcasts, and breaking news on addiction therapy research, treatment, and drug development.

Pain

The HCPLive pain page is a resource for medical news and expert insights on pain medicine. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for acute pain, chronic pain, addiction medicine, and more.

The Shifting Field of Care of Opioid Use Disorder, with Bobby Mukkamala, MD

Initiation of the MOMENTUM clinical trial will explore the prevalence of endogenous hypercortisolism in patients with resistant hypertension.

Dyslipidemia

Hypertension

The HCPLive hypertension page is a resource for medical news and expert insights on high blood pressure. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for hypertension, and more.

MOMENTUM Examines Hypercortisolism in Hypertension, with Deepak L. Bhatt, MD, MPH, MBA

Latanya Benjamin, MD, and Lindsay Ackerman, MD, joins The Medical Sisterhood in a live recording at AAD 2025 to discuss advocacy, mentorship, and empowerment.


The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

The Medical Sisterhood: Empower Hour at AAD 2025

A study found ceftriaxone was the most common drug to lead to anaphylaxis in children.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Pediatrics

Pediatrics page, resources on the topics of medical news and expert insight into childhood health care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on pediatric disease research, treatment, and drug development.

Antibiotics are the Most Common Drugs to Induce Anaphylaxis

Furie shared how Obinutuzumab could enrich the treatment landscape of LN.

Latest News

Diabetes Dialogue: Bionic Pancreas Brings AID to Primary Care & Telehealth

Oxypurinol Formulation May Be Adapted for Gout Treatment

Automated Insulin Delivery Effectively Lowers HbA1c in Type 2 Diabetes

Low-Dose Doxycycline Effective for Managing Lymphocytic Scarring Alopecia Symptoms

When to Refer a Patient with Suspected ISM to an Allergist, with Patricia Lugar, MD